ANKS3

Across TCGA pan-cancer cohorts, ANKS3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKS3 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ANKS3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ANKS3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where ANKS3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	1.000	0.780	.008	15	view →
PDAC	DFS	Median	II,III,IV	0.910	0.631	.004	13	view →
HNSC	DFS	Median	II,III,IV	0.882	1.000	.012	5	view →
CCRCC	OS	Median	All	0.775	0.899	.029	4	view →
LSCC	OS	Median	All	0.773	1.000	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKS3–LUAD (OS)

Open the LUAD breakdown →